Active Protocols
For prospective studies, click on the protocol number to be taken to a web page describing the study.
| Protocol | Details |
|---|---|
| TBCRC 003 | Protocol Title: A Phase II Study of Lapatinib in Combination with Trastuzumab in Patients with HER2-Positive, Metastatic Breast Cancer. Participating Centers: Baylor College of Medicine, Dana Farber Cancer Center / Harvard Cancer Center, Mayo Clinic Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of Chicago, University of North Carolina at Chapel Hill / Lineberger Cancer Center, Vanderbilt-Ingram Cancer Center |
| TBCRC 010 | Protocol Title: Phase I/II study of dasatinib + zoledronic acid for the treatment of breast cancer bone metastasis. Participating Centers: Duke University Medical Cancer Center, MD Anderson Cancer Center, University of Chicago |
| TBCRC 011 | Protocol Title: Bicalutamide for the Treatment of Androgen Receptor Positive (AR+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER/PR-) Metastatic Breast Cancer Patients: A Phase II Feasibility Study. Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Duke University Medical Cancer Center, Mayo Clinic Cancer Center, Memorial Sloan-Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of North Carolina at Chapel Hill/ Lineberger Cancer Center |
| TBCRC 012 | Protocol Title: ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer . Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University / Lombardi Cancer Center, Indiana University Simon Cancer Center, Mayo Clinic Cancer Center, Memorial Sloan-Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center |
| TBCRC 013 | Protocol Title: A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer. Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University / Lombardi Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago, University of Michigan Comprehensive Cancer Center, University of North Carolina at Chapel Hill/ Lineberger Cancer Center, University of Pittsburgh Cancer Institute, Vanderbilt-Ingram Cancer Center |
| TBCRC 014 | Protocol Title: Validation and Generalizability of Genomic Predictors for Benefit from Adjuvant Anthracycline and Taxane Based Chemotherapy in HER2-Negative Breast Cancer Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Georgetown University/ Lombardi Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, Memorial Sloan-Kettering Cancer Center, New York University, University of California San Francisco |
| TBCRC 015 | Protocol Title: Investigation of Genetic Determinants of Capecitabine Toxicity Participating Centers: Baylor College of Medicine, Duke University Medical Cancer Center, Georgetown University/ Lombardi Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of Chicago, University of Michigan Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center |
| TBCRC 018 | Protocol Title: A Phase II Study of the PARP Inhibitor Iniparib (BSI-201), in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University/ Lombardi Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, MD Anderson Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of Chicago, University of Michigan Comprehensive Cancer Center, University of North Carolina at Chapel Hill/ Lineberger Cancer Center , University of Pittsburgh Cancer Institute, Vanderbilt-Ingram Cancer Center
|
| TBCRC 020 | Protocol Title: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Lobular Neoplasia of the Breast by Core Needle Biopsy Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Georgetown University/ Lombardi Cancer Center, Indiana University Simon Cancer Center, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of California San Francisco, University of North Carolina at Chapel Hill/ Lineberger Cancer Center, Vanderbilt-Ingram Cancer Center |
| TBCRC 021 | Protocol Title: A Phase 2 Study of BMS-754807 Combined with Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects with Acquired Resistance to Non-Steroidal Aromatase Inhibitors Participating Centers: Duke University Medical Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of Chicago, University of Minnesota, University of North Carolina at Chapel Hill/Lineberger Cancer Center |
| TBCRC 022 | Protocol Title: A Phase II Trial of HKI-272 (Neratinib) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases Participating Centers: Baylor College of Medicine, Dana Farber Cancer Center/ Harvard Cancer Center, Duke University Medical Cancer Center, Georgetown University/ Lombardi Cancer Center, Johns Hopkins University, University of Alabama at Birmingham Comprehensive Cancer Center, University of Michigan Comprehensive Cancer Center, University of Pittsburgh Cancer Institute |
| TBCRC 023 | Protocol Title: A Randomized Multicenter Phase II Neoadjuvant Trial of Lapatinib, Trastuzumab, with or without Endocrine Therapy for 12 weeks vs. 24 weeks in patients with HER2 Overexpressing Breast Cancer Participating Centers: Baylor College of Medicine, Duke University Medical Cancer Center, Indiana University Simon Cancer Center, Johns Hopkins University, Mayo Clinic Cancer Center, MD Anderson Cancer Center, University of Alabama at Birmingham Comprehensive Cancer Center, University of Chicago, University of Pittsburgh Cancer Institute |
| TBCRC 024 | Protocol Title: A Phase 1 Study of Veliparib Administered Concurrently with Chest Wall and Nodal Radiation Therapy in Patients with Inflammatory or Loco-regionally Recurrent Breast Cancer Participating Centers: Dana Farber Cancer Center/ Harvard Cancer Center, Duke University Medical Cancer Center, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, University of Michigan Comprehensive Cancer Center |
| |